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Summary Conflicting results have been published on the prognostic significance of t(14; 18) in follicular
lymphoma: Yunis et al. (1989) reported that its presence indicated poor response to therapy and short
survival, whereas Levine et al. (1988) showed no difference in prognosis between cases with and without the
translocation. However these results were based on small series of cases and on follow-up periods (no longer
than 7 years) which are relatively short for a disease with such a slow clinical evolution. Here we report an
investigation of 70 cases of follicular lymphoma with long term follow-up data (up to 17 years). This series has
been studied for the presence of the 14;18 translocation and for the expression of bcl-2 protein. Our results
show that there are no grounds for considering either the 14;18 translocation or the expression of the bcl-2
protein to be useful prognostic markers in clinical practice.
A controversial issue concerning the 14; 18 chromosomal
translocation is whether its presence, in approximately 70%
of cases of follicular lymphoma (Pezzella et al., 1990a), has
any prognostic significance. Conflicting results have been
published: in 1989 Yunis et al. reported a series of 20 cases,
analysed by cytogenetics and Southern blotting, in which the
presence of the translocation was associated with a poor
response to therapy and short survival, whereas in 1988
Levine et al. had showed no difference in survival between 30
patients with and without the translocation detected cyto-
genetically. However these two studies were based on small
numbers of patients and follow-up periods of no longer than
84 months.
The availability of monoclonal antibodies against bcl-2
protein (Pezzella et al., 1990b) which work on paraffin-
embedded lymph node biopsies (Gaulard et al., 1991), and
the possibility of detecting bcl-2 rearrangement in the same
type ofmaterial using the polymerase chain reaction (Pezzella
et al., 1990a), have allowed us to carry out a long term
retrospective study (using biopsy specimens dating from as
far back as 1960) of whether bcl-2 protein expression and/or
bcl-2 gene rearrangement have any prognostic significance.
Materials and methods
Tissue samples
Fresh frozen and/or paraffin embedded tissue samples from
70 cases of follicular lymphoma (35 men and 35 women)
were obtained via the routine diagnostic histopathology
services of the John Radcliffe Hospital, Oxford and of the
Rikshospitalet, Copenhagen. Frozen samples from 20 cases
were stored at - 70°C until use; in six of these cases only
scanty material was available and all was used for DNA
extraction. The diagnosis of follicular lymphoma was based
on conventional morphological examination of paraffin
embedded material and on immunohistological staining of
frozen sections. Twenty cases were classified, according to the
Working Formulation (The non Hodgkin's lymphoma
pathologic classification project, 1982), as type B (predomi-
nantly small cleaved cells), 40 as type C (mixed, small cleaved
and large cells) and ten as type D (predominantly large cells).
Patients
Patients were either from the Radiotherapy Department,
Churchill Hospital, Oxford or the Department of Internal
Medicine, Rikshospitalet, Copenhagen and they were treated
with chemo and/or radiotherapy. The clinical follow-up
ranged from 4 months to 17' years with a median of 4.1
years. Thirty-six cases were followed until death, 32 are still
alive and two were lost to follow-up after 30 and 39 months.
Immunohistochemistry
Immunohistological analysis for bcl-2 was performed on
cryostat or paraffin sections using the APAAP method (Cor-
dell et al., 1984).
Southern blotting andpolymerase chain reaction
Southern blotting for detection of rearrangement in the
major, the minor and the 5' breakpoint regions of the bcl-2
gene was performed as described (Pezzella et al., 1990a;
Tsujimoto et al., 1987).
PCR for the detection of rearrangements in major and the
minor breakpoint regions was performed as reported
previously (Pezzella et al., 1990a). A 250 bp fragment of
P-globin gene was amplified as a positive control.
Statistical analysis
Actuarial survival curves were plotted using the method of
Kaplan and Meier (1958), with statistical significance cal-
culated using the Logrank test (Peto et al., 1977) and the
hazard ratio and its confidence interval as described by Alt-
man (1991). Homogeneity of age in the different groups was
assessed by calculating the value of F with one-way analysis
of variances (Armitage & Berry, 1987).
Results
The survival curve of the whole patient population is shown
in Figure 1.
Bcl-2 protein expression
Immunostaining for bcl-2 was successful on 64 node biopsies
(14 frozen and 50 paraffin embedded sections). Details of
these are reported in Table I.
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Figure 1 Survival curve of all follicular lymphoma patients
included in the present study.
Table I Characteristics of 64 patients with follicular lymphoma in
which the expression of bcl-2 protein was assessed by
immunostaining
Staining
Age
Median
Mean
F value
Sex (M/F):
Diagnosis
Follicular, predominantly
small cleaved (B)
Follicular, mixed (C)
Follicular, predominantly
large cleaved (D)
Bone marrow involvement
(26 patients):
present/absent
Clinical stage (32 patients):
I
II
III
IV
0)
0)
.0
.0
Co.
.0
.0
0~
Positive
(n = 55)
33-81
60
56.8
P >0.05 (n.s.)
25/30
15
36
4
Negative
(n = 9)
43-80
62
63.5
5/4
4
6
10/13
3
4
7
13
1/2
2
0
1
2
Months
Figure 2 Survival curves of follicular lymphoma patients vs
expression of bcl-2 protein. Bcl-2 staining pattern: -El-
positive = 55; -*- negative = 9.
Two patterns of staining were observed:
(1) In 55 cases the great majority of neoplastic cells were
bcl-2 positive. bcl-2 rearrangement was found in 24 out
of 51 cases on which PCR and/or Southern blotting
could be performed.
(2) In nine cases the neoplastic follicles were bcl-2
negative. PCR and/or Southern blotting were negative
in each of the six cases which could be analysed.
It is worthy of note (as shown in Table I) that the last
category (i.e. bcl-2 negative lymphoma) predominated (55%)
in group D (large cell type) whereas it accounted for only 6%
and 7.5% of cases respectively in groups B and C.
Survival curves for each group of patients showed close
overlap with no statistically significant differences (Figure 2).
The hazard ratio was 1.02 with a confidence interval at 95%
from 0.4 to 2.61.
Bcl-2 gene rearrangement
In 61 cases DNA was suitable for either Southern blotting
and/or PCR. In 27 cases the bcl-2 gene was rearranged (14
by Southern blot and 13 by PCR). To identify cases without
bcl-2 rearrangement we followed two strategies. When frozen
material was available Southern blotting was performed, and
eight cases without bcl-2 rearrangement were found in this
way. When only paraffin sections were available rearrange-
ment was considered to be absent only when cases, from
which it was possible to amplify a 250 bp P-globin sequence,
were negative by both PCR (for rearrangement) and
immunostaining for bcl-2 protein expression (since break-
points outside the amplified regions can occasionally occur).
Four further cases were identified in this way.
There were no differences in clinical and histological
features between cases with and without bcl-2 rearrangement
(Table II). Survival curves for these patients were similar,
with no significant differences between them (Figure 3). The
hazard ratio was 2.08 with a confidence interval at 95% from
0.83 to 6.81.
Table H Characteristics of 39 patients with follicular lymphoma in
relation to bcl-2 rearrangement
bcl-2 gene
Rearranged Germline
(n = 27) (n = 12)
Age 34-81 31-79
Median 58 60.5
Mean 58 57
F value P >0.05 (n.s.)
Sex (M/F): 11/16 6/6
Diagnosis
Follicular, predominantly 10 2
small cleaved (B)
Follicular, mixed (C) 15 7
Follicular, predominantly 2 3
large cleaved (D)
Bone marrow involvement
(21 patients):
present/absent 5/9 3/4
Clinical stage (16 patients):
I 1 1
II 0 0
III 6 1
IV 4 3
0 60 120 180 240
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Figure 3 Survival curves of follicular lymphoma patients with
and without evidence of bcl-2 gene rearrangement. -0- re-
arranged = 27; -*- germline = 12.bcl-2 AND PROGNOSIS IN FOLLICULAR LYMPHOMA 89
Discussion
A first problem in the present study is that the evaluation of
prognosis could have been affected by the heterogeneity of
treatment received by patients because of their provenance
from two different centres over a period of 30 years. How-
ever the actuarial survival curve for our series (Figure 1) is
consistent with the literature (The non-Hodgkin's lymphoma
pathologic classification project, 1982) indicating that the
validity of our observations is not altered by such a problem.
Our results are at variance with the findings of Yunis et al.
(1989). These authors investigated a series of 20 follicular
lymphomas and concluded that cases with 14; 18 transloca-
tion had a significantly worse prognosis. We have been unable
to confirm this finding, either in relation to rearrangement of
the bcl-2 gene or to bcl-2 protein expression. The series of
Yunis et al. was composed exclusively of follicular lym-
phomas with a large cell component (i.e. mixed or predomi-
nantly large cell types) and to make as close' a comparison as
possible with his data we also analysed the survival of the
same histological categories in our own study. However we
could still find no difference (data not shown). It is therefore
probable that the apparent association between t(14;18) and
prognosis reported by Yunis et al. reflects the small number
of cases in their study.
A similar criticism could be raised against the current
study since although the overall number of cases (70) is
considerably higher than in previously reports, the number
negative for bcl-2 protein expression or not rearranged at the
bcl-2 gene, is relatively low. However the statistical analysis
of the confidence limits of the hazard ratio in this study,
especially for the bcl-2 protein expression (from 0.4 to 2.6 at
95%) indicates that a dramatic difference between the positive
and negative cases can be excluded.
The presence of abnormal levels of bcl-2 is not sufficient
for the neoplastic transformation of cell lines (Vaux et al.,
1988); this finding is supported by the identification of
t(14;18) in reactive lymph nodes (Limpens et al., 1990). If
one accepts that bcl-2 deregulation gives a limited growth
advantage, that it plays a role early in the neoplastic process,
and that further events are likely to be needed for the
evolution of the neoplasia, then it is perhaps not surprising
that neither the 14;18 translocation nor bcl-2 expression are
closely linked with the rate of progression of the disease.
Indeed it is possible, as recently suggested (Yonish-Rouach et
al., 1991) that alteration of other genes, that are also
involved in the mediation of apoptosis, could produce similar
effects in the absence of bcl-2 deregulation. This could then
lead to bcl-2 negative lymphomas with a biological and clinical
behaviour similar to that observed in the bcl-2 positive ones.
In conclusion, whatever the roles of bcl-2 gene rearrange-
ment and/or protein expression may be in the development of
follicular lymphoma, they show no obvious correlation with
clinical behaviour.
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